Genflow Biosciences PLC Announces Update on Animal Health Program

Rhea-AI Summary

Genflow Biosciences (OTCQB:GENFF) provided an update on its Dog Aging (GF-1004) proof-of-concept trial testing a centenarian SIRT6 gene therapy in elderly dogs.

Repeat administration was completed in October 2025 in the randomized, controlled study of 28 beagles aged 10+, with no ill or adverse effects observed after the second dosing. The dogs enter a follow-up period expected to conclude in January 2026. The company highlighted potential animal-health commercial opportunities and continued partnership development while advancing to next-stage evaluation.

Positive

• Second SIRT6 administration showed no adverse effects
• Study cohort: 28 beagles aged 10+
• Follow-up scheduled to conclude in January 2026
• Company pursuing near-term animal health commercial opportunities

Negative

• No efficacy or clinical outcome data disclosed from the trial
• Small sample size (28 animals) limits statistical conclusions
• No binding partnerships or commercial agreements announced

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK, AL / ACCESS Newswire / October 10, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to provide an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.

Genflow's proprietary centenarian SIRT6 gene therapy has now been administered for the second time in its ongoing randomized, controlled trial involving 28 beagles aged 10 years and older. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects observed, while control animals remained untreated. The repeat administration has again demonstrated an excellent safety and tolerability profile, marking a key milestone in the study. The dogs are in a follow-up period expected to conclude in January 2026.

This successful second administration underscores the robustness of Genflow's gene therapy platform and its potential applicability beyond human health. The SIRT6 gene, sourced from human centenarians, plays a vital role in DNA repair, metabolic regulation, and resistance to age-related decline. By leveraging this unique gene variant, Genflow aims to introduce a new class of longevity-based treatments into the multi-billion-dollar global animal health market, targeting improved healthspan, vitality, and lifespan in companion and livestock animals.

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "We're very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we're seeing from established players in the animal health industry. The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform."

With safety confirmed in repeat administration, Genflow will continue to advance its animal health initiative toward the next stage of clinical evaluation and partnership development. The Company remains committed to creating value for shareholders through innovation, collaboration, and leadership in the emerging field of genetic longevity therapeutics.

Contacts

Genflow Biosciences		Harbor Access
Dr Eric Leire, CEO		Jonathan Paterson, Investor Relations
+32-477-495-881		+1 475 477 9401
		Jonathan.Paterson@Harbor-access.com

Corporate Brokers

Capital Plus Partners Ltd

Jon Critchley, +44207 432 0501

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

FAQ

What did Genflow (GENFF) announce about its Dog Aging GF-1004 trial on October 10, 2025?

Genflow announced a successful second administration of its SIRT6 gene therapy in the GF-1004 dog trial with no adverse effects observed.

How many dogs are enrolled in Genflow's GF-1004 study and what are their ages?

The randomized, controlled trial involves 28 beagles aged 10 years and older.

When will Genflow complete follow-up for the dog study (GENFF)?

The follow-up period is expected to conclude in January 2026.

Did Genflow report efficacy results for the SIRT6 therapy in dogs?

No efficacy or outcome data were reported; the update describes safety and tolerability only.

What commercial plans did Genflow (GENFF) mention for its animal health program?

Genflow said it is advancing toward next-stage clinical evaluation and seeks partnership development in the animal health market.

Does the GF-1004 update include any signed partnerships or deals for GENFF?

No signed partnerships or commercial agreements were disclosed in the announcement.